Highlights

  • Racura Oncology (ASX:RAC) is progressing the Phase 1a/b HARNESS-1 trial evaluating RC220 in EGFR-mutant non-small cell lung cancer.
  • The first HARNESS-1 patient completed the initial safety review without dose-limiting toxicities.
  • CPACS Phase 1 trial of RC220 with doxorubicin progressed to the next dose level.
  • Racura reported A$34.3 million in cash at 30 June 2026, supporting operations into calendar 2028.

Racura Oncology (ASX:RAC) is advancing its RC220 clinical development programmes following progress in early-stage oncology trials. The company is focused on evaluating RC220 across multiple indications, including lung cancer, acute myeloid leukaemia and cardioprotection applications.

What happened

Racura’s lead programme, HARNESS-1, is a Phase 1a/b study evaluating RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer.

The company dosed its first patient at Monash Health in Victoria and provided a safety update on 29 July 2026.

The independent safety review committee reported no dose-limiting toxicities and no treatment-related safety concerns during the formal observation period.

The patient later developed Grade 2 colitis, with the cause under investigation. Following the review, Racura decided to dose the second patient at the same 50 mg/m² level rather than escalate immediately.

The company is continuing enrolment, with additional eligible patients awaiting participation.

Separately, Racura reported progress from the CPACS Phase 1 study of RC220 combined with doxorubicin. The first cohort of three patients demonstrated an acceptable safety profile without dose-limiting toxicity at 40 mg/m², allowing escalation to 80 mg/m².

CPACS is enrolling patients in Australia and Hong Kong, with South Korea expected to participate.

The numbers investors need to know

Racura’s key asset is RC220, a proprietary formulation of (E,E)-bisantrene designed to address previous solubility limitations associated with the original compound.

The company is progressing RC220 across three programmes:

  • Phase 3 development in acute myeloid leukaemia.
  • HARNESS-1 in EGFR-mutant non-small cell lung cancer.
  • CPACS in solid tumours.

HARNESS-1 begins dose escalation at 50 mg/m² intravenously. The Phase 1a component is expected to enrol approximately 12 to 40 patients before progressing to a randomised Phase 1b stage involving approximately 40 patients.

Racura reported A$34.3 million in cash at the end of the June 2026 quarter, supporting operations into calendar 2028.

The company raised approximately A$25.2 million through Piggyback Option conversions and completed a A$1 million strategic Placement to strengthen its funding position.

Business outlook and key considerations

Racura’s near-term focus remains clinical execution across its RC220 programmes.

Key milestones include HARNESS-1 dose escalation decisions, additional patient enrolment, CPACS progression and future clinical data updates.

The company’s progress will depend on safety outcomes, trial recruitment, efficacy signals and the ability to advance RC220 towards later-stage development.

Bull case

Racura is developing RC220 across multiple potential applications using a molecule with previous human exposure history.

The company has highlighted that more than 1,500 patients have previously received bisantrene, providing historical safety information for the underlying compound.

HARNESS-1 targets EGFR-mutant lung cancer, where resistance to existing treatments remains a clinical challenge. The company’s approach focuses on a different biological mechanism through targeting c-MYC pathways.

A cash position supporting operations into calendar 2028 provides time to generate additional clinical data without immediate funding pressure.

Bear case and risks

Racura remains in the early stages of clinical development for its newer RC220 indications, and current patient numbers are limited.

HARNESS-1 must still establish safety parameters, dose levels and potential efficacy outcomes. The Grade 2 colitis event highlights the uncertainty of early-stage oncology trials.

Clinical trial recruitment, regulatory outcomes and future study costs remain key risks.

Additional risks include the need for future capital, competition in oncology Drug Development and uncertainty around translating preclinical findings into human outcomes.

What comes next

The next major milestone is the HARNESS-1 safety review committee assessment, expected approximately six to eight weeks after the 29 July update.

Investors will also monitor CPACS progression at the higher dose level, the Global Cardio-Oncology Summit presentation in October 2026, patient enrolment updates and future clinical trial data.

Conclusion

Racura Oncology (ASX:RAC) is progressing multiple RC220 clinical programmes while continuing early-stage evaluation of its oncology platform.

The company has advanced patient dosing, safety reviews and trial expansion activities while maintaining funding support through calendar 2028. The next phase of progress will depend on clinical data, trial execution and evidence that RC220 can demonstrate therapeutic potential.